Filing Summary
Registrant: The filing is for IMARA Inc. (Nasdaq: IMRA), not Enliven Therapeutics, Inc. It is a Form 10-Q for the quarter ended March 31, 2020, filed May 7, 2020. IMARA is a clinical-stage biopharmaceutical company developing IMR-687 for sickle cell disease (SCD) and beta-thalassemia; it has no approved products and has generated no product revenue.
Financial Results and Position
| Metric | Q1 2020 | Q1 2019 or comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $5.8 million | $3.6 million |
| General and administrative expense | $1.6 million | $0.6 million |
| Total operating expenses / operating loss | $7.4 million | $4.2 million |
| Net loss | $7.2 million | $4.2 million |
| Operating cash used | $9.5 million | $2.4 million |
| Cash and cash equivalents | $86.7 million at March 31, 2020 | $4.9 million at December 31, 2019 |
| Short-term investments | $19.1 million at March 31, 2020 | $24.0 million at December 31, 2019 |
| Total cash, cash equivalents and investments | $105.9 million at March 31, 2020 | $28.9 million at December 31, 2019 |
| Total liabilities | $5.1 million | $4.4 million at December 31, 2019 |
Margins are not meaningful because the company had no revenue. No material debt or credit facility is reported. The quarter's $7.2 million net loss included $7.9 million of accretion associated with a beneficial conversion feature of Series B preferred stock; loss attributable to common stockholders was $15.1 million, or $4.31 per share. The accretion was a noncash deemed dividend, not operating expense.
Material Changes and Financing
- Operating expenses increased 75% year over year. R&D rose by approximately $2.2 million, principally from clinical development and manufacturing costs for IMR-687 and higher personnel costs. G&A increased by approximately $0.9 million, reflecting higher personnel, professional and operating costs.
- In February 2020, IMARA raised approximately $17.1 million net from a Series B preferred-stock issuance. Its March IPO raised $75.2 million gross from 4.7 million shares; the underwriters exercised the over-allotment option in April for an additional $11.3 million gross. The filing reports approximately $76.5 million in total net IPO proceeds including the over-allotment.
- At the IPO closing, all outstanding preferred stock converted into 11.2 million common shares. Common shares outstanding were 16.6 million at March 31 and 17.3 million at May 1, 2020. A 1-for-6.299 reverse stock split was effected in February.
Outlook, Risks and Unusual Items
- Management expected Phase 2a SCD top-line data in Q4 2020. It planned to begin treating patients in Phase 2b trials for SCD and beta-thalassemia in the first half of 2020 and expected interim data in the first half of 2021; the filing cautions that COVID-19 could delay these timelines. These are plans, not financial guidance.
- Management said the March 31 cash, cash equivalents and investments were expected to fund operations and capital requirements into mid-2022, subject to assumptions and potential changes in plans. Separately, the liquidity note says proceeds and available funds were expected to cover at least 12 months from filing. The filing does not clearly reconcile these runway statements.
- COVID-19 had not materially affected Q1 financial condition, results or liquidity, but could disrupt clinical enrollment, trial operations, manufacturing and supply, regulatory review, capital access and future liquidity. Employees were temporarily working remotely and travel was suspended.
- The company reported recurring operating losses and negative operating cash flows, an accumulated deficit of approximately $62.0 million and continuing expected losses. It stated that additional funding would be needed; financing may be unavailable or dilutive, and could require delaying or reducing development.
- Key risks include dependence on IMR-687, clinical and regulatory uncertainty, small patient populations, competition, reliance on third-party manufacturers and clinical research organizations, and intellectual-property risks. The Lundbeck license provides for potential milestone payments of up to $23.5 million for licensed compounds and tiered royalties; no payment was made in Q1.
- The company recorded $48,000 of unrealized investment losses; it concluded there was no other-than-temporary impairment. Management said disclosure controls were effective and reported no material change in internal control over financial reporting.
Investor Verification Priorities
- Confirm the registrant and ticker: this filing identifies IMARA Inc. (IMRA), not Enliven Therapeutics, Inc.
- Track Phase 2a readout timing and whether COVID-19 affected enrollment, trial conduct or the planned Phase 2b starts.
- Reconcile the stated cash runway through mid-2022 with the liquidity note's minimum 12-month statement, and monitor quarterly operating cash use.
- Verify financing proceeds and share-count changes, including the April over-allotment and resulting dilution.
- Assess clinical efficacy and safety evidence, trial endpoints, manufacturing continuity, and future capital needs; the filing provides no product revenue or profitability outlook.